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Effects of vitamin E on cardiovascular outcomes in people
with mild-to-moderate renal insufficiency: Results of the HOPE
Study.
Background. A controlled trial reported cardiovascular ben-
efits of vitamin E in terminal renal insufficiency. There are no
data for renal insufficiency before the stage of terminal renal
failure. We evaluated effects of vitamin E supplementation on
cardiovascular and renal outcomes in 993 people with a serum
creatinine ≥1.4 to 2.3 mg/dL.
Methods. Post-hoc analysis of a randomized trial that com-
pared treatment with natural source vitamin E (400 IU/day) to
placebo in 9541 people, 993 of which had renal insufficiency.
Participants had either known cardiovascular disease or dia-
betes and at least one additional coronary risk factor. Exclusion
criteria included a serum creatinine >2.3 mg/dL and dipstick-
positive proteinuria. The primary study outcome after an av-
erage of 4.5 years was the composite of myocardial infarction,
stroke, or cardiovascular death. Secondary outcomes included
revascularizations, total mortality, and clinical proteinuria.
Results. In renal insufficiency, vitamin E supplementation had
a neutral effect on the primary study outcome, on each compo-
nent of the composite primary outcome, and on all secondary
outcomes. Two hundred twenty-four primary outcomes, 23%
of the vitamin E group and 22.1% of the placebo group, rela-
tive risk 1.03 (95% CI, 0.79–1.34; P = 0.82), were observed, and
585 secondary outcomes, including death in 17% and 18.8% of
the vitamin E and placebo groups, respectively (RR 0.88, 95%
CI, 0.66–1.18; P = 0.40). There was no effect of vitamin E on
progression of proteinuria.
Conclusion. In people with mild-to-moderate renal insuffi-
ciency at high cardiovascular risk, vitamin E at a dose of 400 IU/
day had no apparent effect on cardiovascular outcomes.
A full listing of the HOPE Investigators has been previously published
(see reference 13).
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Even in the absence of classic risk factors, people with
renal disease have an elevated risk for cardiovascular dis-
ease [1–3]. This renal-cardiovascular association is well
established for advanced renal insufficiency, especially
for end-stage renal disease [2]. Recently, this association
has also been reported for mild-to-moderate degrees of
renal insufficiency [1, 3]. There are many potential causes
that could explain why renal insufficiency is associated
with a staggering cardiovascular risk [1, 3]. Oxidative
stress has been hypothesized to be an important mech-
anism of atherogenesis in renal insufficiency. Renal in-
sufficiency is associated with increased oxidative stress
[4–6], and oxidative modification of low-density lipopro-
tein (LDL) is an important step in the development and
progression of atherosclerosis in experimental studies
[4, 5, 7].
In support of the foregoing information, small clinical
studies have reported improved renal function and nerve
conduction in patients receiving high-dose a-tocopherol
[8, 9]. Moreover, one prospective trial examined if the an-
tioxidant effect of supplementation with vitamin E can
reduce the burden of atherosclerotic complications in
people with end-stage renal disease. In fact, the Sec-
ondary Prevention with Antioxidants of Cardiovascular
disease in End-stage renal disease (SPACE) trial reported
a benefit of vitamin E on major cardiovascular outcomes
in those patients [10]. These data in people with end-stage
renal disease are at variance with the vast majority [11],
but not all [12], of other major trials that observed a neu-
tral effect of vitamin E on cardiovascular outcomes.
In the Heart Outcomes Prevention Evaluation
(HOPE) study, 9541 patients at high risk for cardiovas-
cular events were randomly allocated to natural source
vitamin E 400 IU/day, or placebo, in addition to usual
medical therapy. The study population included 993 peo-
ple with mild-to-moderate renal insufficiency. The lack
of effect of vitamin E on cardiovascular outcomes in
the entire HOPE study population and in the diabetic
1375
1376 Mann et al: Effects of vitamin E in renal insufficiency
subgroup has been recently reported [13, 14]. In the
present post-hoc analysis we tested the hypothesis that
the subgroup with mild-to-moderate renal insufficiency
benefited from vitamin E supplementation, as did peo-
ple with more advanced renal insufficiency in the SPACE
study [10].
METHODS
Detailed descriptions of the HOPE and Microalbu-
minuria, Cardiovascular and Renal Outcomes in the
Heart Outcomes Prevention Evaluation Study (MICRO-
HOPE) study designs and protocols have been published
[15, 16]. In brief, we enrolled people with and without dia-
betes at high risk for cardiovascular events. The study was
conducted in 19 countries in North and South America
and in Europe. Patients were eligible if they were 55 years
or older, had a history of cardiovascular disease (coronary
artery disease, stroke, or peripheral arterial disease), or
diabetes in the presence of at least one additional cardio-
vascular risk factor [total cholesterol >5.2 mmol/L, HDL
cholesterol ≤0.9 mmol/L, hypertension (defined as use of
medication(s) to treat high blood pressure or blood pres-
sure at the time of recruitment >160 mm Hg systolic or
>90 mm Hg diastolic), known microalbuminuria, or cur-
rent smoking]. Key exclusion criteria included dipstick-
positive proteinuria at baseline, serum creatinine >200
lmol/L (2.3 mg/dL), history of congestive heart failure,
or known low left ventricular ejection fraction (<40%),
hyperkalemia, uncontrolled hypertension, myocardial in-
farction, unstable angina, or stroke within one month
prior to study enrollment, and use of or intolerance to
vitamin E or ACE inhibitors. All study participants pro-
vided written informed consent, and the study protocol
was approved by the Research Ethics Board of each par-
ticipating center.
This publication refers to post-hoc analyses restricted
to 993 participants with documented renal insufficiency
at baseline. Recent data suggest that in individuals
>55 years, a serum creatinine concentration ≥1.4 mg/dL
(125 lmol/L) is a good indicator of a glomerular filtra-
tion rate <80 mL/min [17]. Therefore, prior to beginning
this post-hoc analysis, a serum creatinine concentration
≥125 lmol/L (1.4 mg/dL) was used to differentiate peo-
ple with and without renal insufficiency. Serum creati-
nine was measured locally at each of the 267 participating
centers.
Study design and outcomes
The study had a 2 × 2 factorial design, with random-
ization to natural source vitamin E (RRR-a-tocopheryl
acetate) 400 IU or placebo, and to 10 mg ramipril or
placebo; both study drugs were administered once daily.
After randomization, patients were evaluated at 1 month
and thereafter every 6 months. As part of the MICRO-
HOPE substudy, urinary albumin excretion was mea-
sured at baseline, and at study end (median 4.5 years)
by measuring the albumin/creatinine ratio in the first
morning urine sample. Microalbuminuria was defined
based on definitions available in 1993 at the time of study
initiation, as an albumin/creatinine ratio of 2 mg/mmol
(18 mg/g creatinine) or higher [16]. Participants with al-
bumin/creatinine ratio higher than 36 mg/mmol after ran-
domization were asked to provide a 24-hour urine sample
that was assayed in their local laboratory for total protein
or urinary albumin. Results of these measurements were
sent to the project office and all cases of overt nephropa-
thy were adjudicated centrally.
The study outcomes have been defined previously [13,
15]. The primary study outcome was the composite of
myocardial infarction, stroke, or death from cardiovas-
cular causes. Secondary end points were total mortality,
hospital admission for congestive heart failure, hospital
admission for unstable angina, revascularization proce-
dures, and the development of overt nephropathy. Overt
nephropathy was diagnosed if the 24-hour urine albumin
was 300 mg or more, if the 24-hour urine total protein
excretion was 500 mg or more, or if the measured albu-
min/creatinine ratio was >36 mg/mmol and no 24-hour
urine result was available [16].
Statistical analysis
Only data from the original intention-to-treat analy-
sis [13] were used for this report. Because of HOPE’s
factorial design, all analyses were stratified for random-
ization to ramipril or placebo. Baseline characteristics
were compared in participants treated with vitamin E
or placebo using chi-square tests for discrete variables
and t tests for continuous ones. Albumin/creatinine ra-
tios were transformed to account for non-normality, and
values were adjusted for the laboratories in which the
assays were performed; they were compared using a
Wilcoxon tests. Time-to-event by group was estimated by
Cox regression stratified by center because the number
of people with renal insufficiency varied significantly by
center (P = 0.006). Kaplan-Meier curves were used to es-
timate survival and were compared by log-rank tests. All
analyses were done using SAS 6.12 for Unix (Cary, NC,
USA).
RESULTS
Patient characteristics
Of the total 9541 participants in the vitamin E arm of
the HOPE study, 993 had documented renal insufficiency
at baseline. Their mean age was 68.4 years, 126 (12.6%)
were women, and 933 (94%) had a history of cardiovas-
cular disease. Baseline characteristics of the HOPE study
participants with renal insufficiency in the vitamin E and
placebo groups were similar (Table 1).
Mann et al: Effects of vitamin E in renal insufficiency 1377
Table 1. Baseline characteristics of participants of the vitamin E arm
of the HOPE study with renal insufficiency
Vitamin E Placebo
N = 499 N = 494 P value
Demographic data
Mean age (SD) years 68.6 (6.8) 68.3 (7.0) 0.4607
Female No. (%) 58.0 (11.6) 68.0 (13.8) 0.3106
Clinical characteristics History of No. (%)
Myocardial infarction 292.0 (58.6) 295.0 (59.7) 0.7288
Coronary artery disease 443.0 (88.8) 425.0 (86.0) 0.1923
Stroke 49.0 (9.8) 36.0 (7.3) 0.1539
Peripheral vascular disease 118.0 (23.6) 117.0 (23.7) 0.9891
Any cardiovascular disease 474.0 (95.0) 459.0 (92.9) 0.1700
No cardiovascular disease 25.0 (5.0) 35.0 (7.1) 0.1700
Hypertension 272.0 (54.5) 278.0 (56.3) 0.5756
Diabetes 154 (30.9) 180 (36.4) 0.0630
Hypercholesterolemia 316.0 (63.3) 323.0 (65.4) 0.4984
Low HDL-cholesterol 115.0 (23.0) 109.0 (22.1) 0.7114
Current smoking 57.0 (11.4) 47.0 (9.5) 0.3261
Baseline measurements mean (SD)
Body mass index (SD) kg/m2 27.5 (4.0) 27.7 (4.4) 0.3279
Heart rate (SD) beats/min 66.5 (11.4) 67.0 (11.3) 0.4574
Systolic blood pressure 140.1 (20.2) 140.6 (19.8) 0.6688
(SD) mm Hg
Diastolic blood pressure 78.7 (10.8) 78.9 (11.3) 0.8202
(SD) mm Hg
Ankle/arm blood pressure 0.8 (0.4) 0.8 (0.4) 0.7236
index SD
Waist/hip ratio 0.9 (0.1) 0.9 (0.1) 0.6904
Waist circumference (SD) cm 98.8 (11.4) 98.8 (11.0) 0.9134
Creatinine (SD) lmol/L 138.7 (16.9) 138.8 (16.2) 0.9199
Other drugs No. (%)
Acetylsalicylic acid/other 403.0 (80.8) 401.0 (81.2) 0.8685
antiplatelet agents
Beta-blockers 249.0 (49.9) 226.0 (45.7) 0.1905
Calcium-channel blockers 126.0 (25.3) 130.0 (26.3) 0.7012
Diuretics 113.0 (22.6) 120.0 (24.3) 0.5405
Hypolipidemic agents 147.0 (29.5) 147.0 (29.8) 0.9180
Vitamin C supplements 22.0 (4.4) 18.0 (3.6) 0.5398
Beta-carotene supplements 6.0 (1.2) 7.0 (1.4) 0.7661
Multivitamins 31.0 (6.2) 28.0 (5.7) 0.7167
The effects of vitamin E on cardiovascular outcomes
and all-cause death
Vital status was ascertained at study end in all patients
in the vitamin E group and in 99.9% in the placebo group;
224 primary and 585 secondary outcomes were observed.
A total of 115 (23%) of the 499 people with renal in-
sufficiency who were assigned to receive vitamin E and
109 (22.1%) of those 494 assigned to placebo had a pri-
mary cardiovascular event, hazard ratio 1.03 (P = 0.82).
Similarly, there were no significant differences between
the study groups in the rates of myocardial infarction,
stroke, or death from cardiovascular causes (Table 2 and
Fig. 1).
There were also no differences between patients as-
signed to vitamin E and those assigned to placebo in any
of the secondary outcomes and in the other cardiovas-
cular outcomes examined (Table 2). The total number of
deaths, 85 in the vitamin E group versus 93 in the placebo
group, was similar (hazard ratio 0.88, P = 0.40).
Effect of vitamin E on albuminuria
Albumin/creatinine ratio was measured in 947 (95%)
participants at baseline, and in 699 (86% of those alive,
699/815) at study end. The albumin/creatinine ratio did
not differ significantly in the two study groups at base-
line or at study end (Fig. 2). Progression of proteinuria,
defined as new microalbuminuria and/or new clinical pro-
teinuria/overt nephropathy, was not different between
groups. Progression of proteinuria from nil to microal-
buminuria or clinical proteinuria occurred in 105 and 110
participants in the placebo and vitamin E group, respec-
tively (P = 0.659), and from microalbuminuria to clinical
proteinuria in 25 participants each (P = 0.890).
DISCUSSION
This analysis of HOPE study participants with mild-to-
moderate renal insufficiency shows that 4.5 years of ther-
apy with natural source vitamin E (RRR-a-tocopheryl
acetate) 400 IU/day has a neutral effect on cardiovascular
outcomes. The results on cardiovascular outcomes appear
robust because a substantial number of outcomes was ob-
served. There were 224 primary and 585 secondary out-
comes. Compliance with study drug was high and similar
in patients randomized to active vitamin E and placebo
[13].
Not shown in this paper, but reported previously [18],
participants with renal insufficiency were older, as com-
pared to the rest of the HOPE study population, more
likely to be male, and had a higher baseline preva-
lence of hypertension, coronary artery disease, peripheral
vascular disease, low HDL, and use of antiplatelet and an-
tihypertensive agents. Systolic blood pressure, urine albu-
min, and waist-to-hip ratio were also higher in this group.
The higher cardiovascular risk profile translated into a
substantially increased rate of cardiovascular outcomes
[18]. Based on the number of cardiovascular events, the
present analysis should have the statistical power to de-
tect an effect, if there was any, of vitamin E on cardiovas-
cular disease.
The Secondary Prevention with Antioxidants of Car-
diovascular disease in End-stage renal disease (SPACE)
study [10] is at variance with the HOPE study results
in people with renal insufficiency. The SPACE trial ran-
domized 196 hemodialysis patients of the greater Tel Aviv
area, mean age 65 years, all with documented cardiovas-
cular disease, 43% with known diabetes, to vitamin E
800 IU/day or to placebo for a mean follow-up 17 months
[10]. Patients assigned to vitamin E had a 54% risk re-
duction (95% CI, 22–73; P = 0.014) of the compos-
ite end point of myocardial infarction, ischemic stroke,
peripheral vascular disease, and unstable angina, and
experienced fewer myocardial infarcts. There were no
significant differences in total mortality. Why did vi-
tamin E fail to demonstrate benefit in people with
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Table 2. Cardiovascular events in the vitamin E and placebo groups
Vitamin E Placebo
N = 499 N = 494
Outcome N% N% RR (95% CI)a P value
Primary outcome
Composite of myocardial infarction, 115.0 (23.0) 109.0 (22.1) 1.03 (0.79–1.34) 0.82
stroke, or death from CV causes
Myocardial infarctionb 81.0 (16.2) 83.0 (16.8) 0.95 (0.70–1.29) 0.76
Strokeb 26.0 (5.2) 25.0 (5.1) 1.00 (0.58–1.73) 1.00
Death from CV causesb 57.0 (11.4) 57.0 (11.5) 0.97 (0.67–1.40) 0.85
Secondary outcomes
Total mortality 85.0 (17.0) 93.0 (18.8) 0.88 (0.66–1.18) 0.40
Unstable angina 76.0 (15.2) 77.0 (15.6) 0.95 (0.69–1.31) 0.77
Heart failure hospitalizations 31.0 (6.2) 28.0 (5.7) 1.08 (0.65–1.80) 0.77
Revascularization procedures 107.0 (21.4) 88.0 (17.8) 1.20 (0.91–1.60) 0.20
Other outcomes
Any heart failure 83.0 (16.6) 63.0 (12.8) 1.32 (0.95–1.84) 0.09
Transient ischemic attacks 33.0 (6.6) 34.0 (6.9) 1.27 (0.75–2.14) 0.38
Unstable angina with ECG changes 27.0 (5.4) 32.0 (6.5) 0.81 (0.49–1.36) 0.43
aRR, relative risk; CI, confidence interval; N, number of people (percentage); CV, cardiovascular.
bA patient may have had more than one event.
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Fig. 1. Kaplan-Meier survival curves for the primary cardiovascular
study outcome (myocardial infarction, stroke, cardiovascular death).
The x-axis indicates the duration of follow-up in days.
mild-to-moderate renal insufficiency while it was bene-
ficial in people with end stage renal disease [10]? First,
the population enrolled in the SPACE trial was at a
higher cardiovascular risk than the present subgroup of
the HOPE trial. The annual cardiovascular event rate of
the SPACE trial was about 3 times that of our popula-
tion [10]. Second, participants of the SPACE study were
treated with a higher dose of vitamin E than in HOPE,
and almost half of the population regularly consumed vi-
tamin C. The vast majority of participants of the HOPE
study did not consume vitamin C (see Table 1). It may
well be that the higher antioxidative potential of higher
vitamin E doses, combined with vitamin C, has different
effects in people with terminal renal insufficiency com-
pared to lower doses of vitamin E in people with mild-
to-moderate renal insufficiency. There is some evidence
0
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Fig. 2. Median urinary albumin/creatinine ratio including 25 and 75
percentiles at baseline (left) and at study end (right) in the placebo and
vitamin E treated groups, respectively.
that people with end-stage renal disease are exposed to a
greater oxidative stress than other populations [4–7, 19,
20]. There is a hypothesis that the combined use of vita-
mins C and E has a superior antioxidant effect to vitamin
E alone [21]. However, the recent results of the Heart
Protection Study do not support a cardiovascular pro-
tective effect of vitamin E and C [22]. Third, the dietary
intake of vitamins, including vitamin E, may be different
in people with or without end-stage renal disease. The
average diet of participants of the HOPE trial may have
provided adequate supplies of vitamin E in a large pro-
portion of individuals, but may have provided inadequate
supplies in the population of the SPACE trial. In other
words, the absolute difference of vitamin E intake be-
tween placebo and actively treated participants may be
substantially greater in the SPACE than in the HOPE
study. In both trials, there is no information on dietary
intake of vitamin E at baseline. Fourth, the results of the
SPACE trial may be a chance finding, because the major-
ity of other large randomized trials did not find an effect
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of vitamin E, alone or in combination with vitamin C,
on cardiovascular events [11], and because SPACE stud-
ied a small sample compared with other trials [11], which
resulted in large confidence intervals based on a broad
composite end point.
In spite of the strong biologic rationale, the random-
ized clinical trials have, with few exceptions, failed to
detect clear benefits of vitamin E supplementation on
the progression of atherosclerotic lesions or on clinical
outcomes [11]. Six recent, large randomized trials have
evaluated the effects of vitamin E on major cardiovas-
cular outcomes. The primary prevention trials include
the Alpha-tocopherol Beta-carotene Cancer Prevention
Study (ATBC) [23], the Collaborative Group of the Pri-
mary Prevention Project (PPP) [24], and Heart Protec-
tion Study [22]; the major trials in secondary prevention
are the Cambridge Heart Antioxidant Study (CHAOS)
[12], the GISSI Prevenzione trial [26], HOPE [13], and a
subset of the ATBC trial [26]. Overall, these large ran-
domized, controlled clinical trials failed to demonstrate
consistent cardiovascular benefits of vitamin E supple-
mentation, as were further supported by a recent meta-
analysis [11].
Interestingly, vitamin E was shown to improve en-
dothelial function in short-term studies [27, 28], and a
large, long-term observational study reported reduced
coronary atherosclerosis progression in women and men
taking vitamin E supplements [29, 30]. Variable effects
were reported on carotid atherosclerosis. The Study to
Evaluate Carotid Ultrasound Changes in patients treated
with Ramipril and vitamin E (SECURE), a HOPE sub-
study in 732 high-risk patients, showed no effect of vita-
min E supplementation for 3 to 5 years on the progression
of carotid atherosclerosis, assessed by ultrasound
methods [31]. The Antioxidant Supplementation in
Atherosclerosis (ASAP) trial [21], however, suggested
benefits in hypercholesterolemic men treated with com-
bined vitamin E and C supplementation, while finding no
benefit in women.
Small clinical studies have reported improved renal
function and nerve conduction in patients receiving high-
dose a-tocopherol [8, 9]. The current study, the largest
to date to evaluate the effects of vitamin E in people
with renal insufficiency, showed neutral effects on pro-
teinuria. The interpretation of those renal data is lim-
ited because urine albumin was measured only once at
the beginning and at study end in all participants of the
HOPE study. Although the drop-out rate of the HOPE
study was very low [13], urine albumin values at study
end were missing in about a third of the population be-
cause of death or missing values. It may be argued that
those with missing values could be those with worse re-
nal outcomes. However, baseline characteristics of those
with and without missing values were identical (data not
shown).
CONCLUSION
Our post-hoc analysis does not support the use of vi-
tamin E to prevent cardiovascular complications in peo-
ple with mild-to-moderate renal insufficiency. Other risk
factors of premature atherosclerosis, such as high blood
pressure and hyperlipidemia, should remain the focus of
treatment.
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